Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. The company was founded in 2011 and is headquartered in Kfar Saba, Israel.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Symbol: NASDAQ:APOP
- CUSIP: N/A
- Web: cellectbio.com
Capitalization:- Market Cap: $44.77 million
- Outstanding Shares: 107,583,000
Average Prices:- 50 Day Moving Avg: $8.09
- 200 Day Moving Avg: $7.89
- 52 Week Range: $2.30 - $13.50
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -7.43
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $0.77 per share
- Price / Book: 10.13
Profitability:- EBIDTA: ($5,560,000.00)
- Return on Equity: -102.64%
- Return on Assets: -74.35%
Debt:- Current Ratio: 8.23%
- Quick Ratio: 8.23%
Misc:- Average Volume: 30,140 shs.
- Beta: 7.92
- Short Ratio: 5.51
Frequently Asked Questions for Cellect Biotechnology (NASDAQ:APOP)
What is Cellect Biotechnology's stock symbol?
Cellect Biotechnology trades on the NASDAQ under the ticker symbol "APOP."
When will Cellect Biotechnology make its next earnings announcement?
Where is Cellect Biotechnology's stock going? Where will Cellect Biotechnology's stock price be in 2017?
2 equities research analysts have issued twelve-month target prices for Cellect Biotechnology's stock. Their forecasts range from $1.00 to $10.00. On average, they anticipate Cellect Biotechnology's share price to reach $5.50 in the next year. View Analyst Ratings for Cellect Biotechnology.
Who are some of Cellect Biotechnology's key competitors?
Some companies that are related to Cellect Biotechnology include aTyr Pharma (LIFE), FULGENT GENETIC (FLGT), Edap Tms S.A. (EDAP), Intec Pharma (NTEC), ArQule (ARQL), ADMA Biologics (ADMA), Lipocine (LPCN), Protalix Biotherapeutics (PLX), Zynerba Pharmaceuticals (ZYNE), ProNAi Therapeutics (SRRA), Dicerna Pharmaceuticals (DRNA), Catasys (CATS), Cardiome Pharma Corporation (CRME), Aeglea BioTherapeutics (AGLE), Brainstorm Cell Therapeutics (BCLI), Vermillion (VRML), Sophiris Bio (SPHS) and Catasys (CATS).
Who owns Cellect Biotechnology stock?
How do I buy Cellect Biotechnology stock?
Shares of Cellect Biotechnology can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cellect Biotechnology's stock price today?
One share of Cellect Biotechnology stock can currently be purchased for approximately $7.80.
MarketBeat Community Rating for Cellect Biotechnology (NASDAQ APOP)MarketBeat's community ratings are surveys of what our community members think about Cellect Biotechnology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Cellect Biotechnology (NASDAQ:APOP) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $5.50 (29.49% downside) |
Analysts' Ratings History for Cellect Biotechnology (NASDAQ:APOP)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 4/4/2017 | Rodman & Renshaw | Reiterated Rating | Buy | $10.00 -> $1.00 | High |  |
| 3/27/2017 | HC Wainwright | Set Price Target | Buy | $10.00 | High | |
(Data available from 9/19/2015 forward)
Earnings History for Cellect Biotechnology (NASDAQ:APOP)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Cellect Biotechnology (NASDAQ:APOP)Current Year EPS Consensus Estimate: $-0.85 EPS
Next Year EPS Consensus Estimate: $-1.05 EPS
Dividend History for Cellect Biotechnology (NASDAQ:APOP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Cellect Biotechnology (NASDAQ:APOP)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Cellect Biotechnology (NASDAQ:APOP)
Latest Headlines for Cellect Biotechnology (NASDAQ:APOP)
| Source: |
|
| Date | Headline |
|---|
 | Corporate News Blog - Amicus Therapeutics Reports Phase-3 Results for Sd-101 in Epidermolysis Bullosa did not Meet Primary Endpoints
finance.yahoo.com - September 15 at 4:19 PM |
 | Cellect Biotechnology (APOP) Announces $4.3M Registered Direct Offering of ADSs
www.streetinsider.com - September 8 at 4:20 PM |
 | Mid-Afternoon Market Update: NCI Building Drops On Downbeat Results; GoPro Shares Spike Higher
www.nasdaq.com - September 7 at 4:00 PM |
| Cellect Biotechnology Announces $4.3 Million Raise in a Registered Direct Offering
finance.yahoo.com - September 7 at 4:00 PM |
| Cellect shares rise 5% after FDA grants its technology orphan drug status
finance.yahoo.com - September 6 at 8:57 PM |
 | Cellect Granted FDA Orphan Nod, Shares Soar
www.baystreet.ca - September 5 at 5:38 PM |
 | Cellect Bio's ApoGraft an Orphan Drug in U.S.; shares up 50% preamarket
seekingalpha.com - September 5 at 5:38 PM |
| Cellect Biotechnology (APOP) Granted FDA Orphan Drug Designation for ApoGraft
www.streetinsider.com - September 5 at 5:38 PM |
| FDA Grants Orphan Drug Status to Cellect's ApoGraft™ for Acute GvHD and Chronic GvHD
finance.yahoo.com - September 5 at 5:38 PM |
| UPDATED: Cellect shares rise 53% after FDA grants its technology orphan drug status
finance.yahoo.com - September 5 at 5:38 PM |
| Cellect Shares Will Be Traded From Next Week Exclusively on NASDAQ
finance.yahoo.com - September 1 at 4:30 PM |
| Cellect Biotechnology Ltd Provides Corporate Update and Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 21 at 4:07 PM |
| Cellect Engages Locust Walk to Support Business Development Activities for Cellect's ApoGraft™
finance.yahoo.com - August 7 at 4:50 PM |
| Cellect Biotechnology (APOP) Granted Russian Patent Covering Any Device & Method Using Flagship Technology
www.streetinsider.com - June 14 at 10:02 AM |
| Following the US, Cellect Receives Russian Patent Covering Any Device and Method Using Cellect's Flagship Technology - the ApoGraft™
finance.yahoo.com - June 14 at 10:02 AM |
| Corporate News Blog - Cellect Biotech Gets Patent for Method of Use for Flagship Technology - ApoGraft(TM)
finance.yahoo.com - June 14 at 10:02 AM |
| Cellect Receives Notice of Allowance from the US Patent & Trademark Office
finance.yahoo.com - June 12 at 4:39 PM |
| Cellect is Moving to Trade Exclusively on the NASDAQ
finance.yahoo.com - June 9 at 3:54 PM |
| Cellect Bio to delist shares on Tel Aviv exchange; ADRs will continue to trade on Nasdaq
seekingalpha.com - June 5 at 6:19 PM |
| Cellect Biotechnology Ltd Provides Corporate Update and Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 29 at 3:57 PM |
| David Braun, Head of Merck Device Business (MD&S), Joins Cellect's Advisory Board
finance.yahoo.com - May 23 at 8:41 AM |
| Cellect Gets Green Light From FDA For ApoGraft IND Submission in the U.S.
finance.yahoo.com - May 3 at 9:31 AM |
| Cellect Biotechnology (APOP) Jumps: Stock Moves 10.5% Higher
finance.yahoo.com - April 7 at 6:44 AM |
| Q1 Roundup: Winners and Losers of Biotech Sector
finance.yahoo.com - April 7 at 6:44 AM |
 | Cellect Biotechnology Ltd. - American Depositary Shares (APOP) Earns Buy Rating from Rodman & Renshaw
www.americanbankingnews.com - April 4 at 1:23 PM |
 | Cellect Biotechnology Gets European Patent
www.investopedia.com - April 3 at 8:53 PM |
 | Cellect Receives Notice of Intention to Grant from European Patent Office for Patent Protecting Company’s Technology in Multiple Indications
us.rd.yahoo.com - April 3 at 3:52 PM |
| Cellect Biotechnology and Impax Laboratories Post Solid Gains
finance.yahoo.com - March 28 at 10:13 AM |
| Cellect Succeeds in First Stem Cell Transplant
www.investopedia.com - March 27 at 3:41 PM |
 | Cellect Biotech stock rises 71% after announcing successful stem cell transplant procedure
www.marketwatch.com - March 27 at 3:41 PM |
 | Why Cellect Biotechnology Stock Is Skyrocketing Today
www.fool.com - March 27 at 3:41 PM |
| Cellect Biotechnology Ltd. - American Depositary Shares (APOP) Given a $10.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - March 27 at 2:49 PM |
| Cellect Announces Successful First Cancer Patient Stem Cell Transplant
finance.yahoo.com - March 27 at 7:56 AM |
| Cellect Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results
finance.yahoo.com - March 23 at 3:59 PM |
| Michael Berelowitz MD., Former Head, Clinical Development and Medical Affairs, Pfizer Specialty Care Business Unit Joins Cellect’s Board of Directors
finance.yahoo.com - March 2 at 3:50 PM |
| World-Renowned Stem Cell Transplantation Expert joins Cellect’s Advisory Board
finance.yahoo.com - February 23 at 3:36 PM |
| Cellect Biotechnology Ltd. (Nasdaq: APOP) to Ring The Nasdaq Stock Market Opening Bell
finance.yahoo.com - February 23 at 3:36 PM |
| Cellect to Ring the NASDAQ Stock Market Opening Bell on Friday, February 24th
finance.yahoo.com - February 23 at 3:36 PM |
| Cellect Announces Positive Clinical Trial Results
finance.yahoo.com - February 21 at 8:31 AM |
| Biotech Industry Poised for a Breakout in 2017? Today's Reports on Cellect Biotechnology and XOMA
finance.yahoo.com - February 16 at 8:30 AM |
| Dual-Listed Cellect to Voluntarily File for Delisting from Tel Aviv Stock Exchange
finance.yahoo.com - February 14 at 4:12 PM |
| Cellect Biotechnology (APOP) Says It Treated First Blood Cancer Patient in Phase I/II Trial of ApoGraft
www.streetinsider.com - February 9 at 1:52 AM |
| First Cancer Patient Treated In Phase I/II Trial of ApoGraft™
us.rd.yahoo.com - February 8 at 3:47 PM |
| Why Cellect Biotechnology Ltd Shares Skyrocketed Higher Today
www.fool.com - February 8 at 3:47 PM |
| Mergers & Acquisitions Could be a Key Catalyst for Biotech Stocks in 2017: Today's Reports on Cellect Biotechnology and Celldex Therapeutics
finance.yahoo.com - February 3 at 3:43 PM |
| Cellect Biotechnology (APOP) Names Dr. Yaron Pereg as CDO
www.streetinsider.com - January 31 at 2:38 AM |
| Dr. Yaron Pereg Appointed as New Chief Development Officer
finance.yahoo.com - January 30 at 4:36 PM |
 | Gainers & Losers Of The Day: TBIO, IMMU, SGMO, BIOC, APRI
www.finanznachrichten.de - January 13 at 1:38 AM |
 | Cellect Biotechnology Ltd. (APOP) Is Surging On Patent News
www.rttnews.com - January 12 at 8:38 PM |
| Cellect Receives Patent Notice of Allowance from US Patent & Trademark Office Protecting Company’s Technology in Multiple Key Indications
us.rd.yahoo.com - January 12 at 3:37 PM |
Cellect Biotechnology (APOP) Chart for Tuesday, September, 19, 2017
